Report cover image

Global Tofacitinib Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 198 Pages
SKU # APRC20557616

Description

Summary

According to APO Research, the global Tofacitinib market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Tofacitinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Tofacitinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Tofacitinib market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Tofacitinib is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Tofacitinib market include Pfizer, Globe Pharmaceuticals, Drug International, Delta Pharma Limited and Beacon Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Tofacitinib, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Tofacitinib, also provides the sales of main regions and countries. Of the upcoming market potential for Tofacitinib, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tofacitinib sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Tofacitinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Tofacitinib sales, projected growth trends, production technology, application and end-user industry.

Tofacitinib Segment by Company

Pfizer
Globe Pharmaceuticals
Drug International
Delta Pharma Limited
Beacon Pharmaceuticals
Tofacitinib Segment by Type

5mg*60 Tablets
5mg*30 Tablets
5mg*14 Tablets
5mg*10 Tablets
10mg*14 Tablets
10mg*10 Tablets
Tofacitinib Segment by Application

Psoriasis
Rheumatoid Arthritis
Ulcerative Colitis
Others
Tofacitinib Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Tofacitinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Tofacitinib market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Tofacitinib significant trends, drivers, influence factors in global and regions.
6. To analyze Tofacitinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tofacitinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tofacitinib industry.
Chapter 3: Detailed analysis of Tofacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Tofacitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Tofacitinib in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Tofacitinib Sales Value (2020-2031)
1.2.2 Global Tofacitinib Sales Volume (2020-2031)
1.2.3 Global Tofacitinib Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Tofacitinib Market Dynamics
2.1 Tofacitinib Industry Trends
2.2 Tofacitinib Industry Drivers
2.3 Tofacitinib Industry Opportunities and Challenges
2.4 Tofacitinib Industry Restraints
3 Tofacitinib Market by Company
3.1 Global Tofacitinib Company Revenue Ranking in 2024
3.2 Global Tofacitinib Revenue by Company (2020-2025)
3.3 Global Tofacitinib Sales Volume by Company (2020-2025)
3.4 Global Tofacitinib Average Price by Company (2020-2025)
3.5 Global Tofacitinib Company Ranking (2023-2025)
3.6 Global Tofacitinib Company Manufacturing Base and Headquarters
3.7 Global Tofacitinib Company Product Type and Application
3.8 Global Tofacitinib Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Tofacitinib Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Tofacitinib Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Tofacitinib Market by Type
4.1 Tofacitinib Type Introduction
4.1.1 5mg*60 Tablets
4.1.2 5mg*30 Tablets
4.1.3 5mg*14 Tablets
4.1.4 5mg*10 Tablets
4.1.5 10mg*14 Tablets
4.1.6 10mg*10 Tablets
4.2 Global Tofacitinib Sales Volume by Type
4.2.1 Global Tofacitinib Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Tofacitinib Sales Volume by Type (2020-2031)
4.2.3 Global Tofacitinib Sales Volume Share by Type (2020-2031)
4.3 Global Tofacitinib Sales Value by Type
4.3.1 Global Tofacitinib Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Tofacitinib Sales Value by Type (2020-2031)
4.3.3 Global Tofacitinib Sales Value Share by Type (2020-2031)
5 Tofacitinib Market by Application
5.1 Tofacitinib Application Introduction
5.1.1 Psoriasis
5.1.2 Rheumatoid Arthritis
5.1.3 Ulcerative Colitis
5.1.4 Others
5.2 Global Tofacitinib Sales Volume by Application
5.2.1 Global Tofacitinib Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Tofacitinib Sales Volume by Application (2020-2031)
5.2.3 Global Tofacitinib Sales Volume Share by Application (2020-2031)
5.3 Global Tofacitinib Sales Value by Application
5.3.1 Global Tofacitinib Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Tofacitinib Sales Value by Application (2020-2031)
5.3.3 Global Tofacitinib Sales Value Share by Application (2020-2031)
6 Tofacitinib Regional Sales and Value Analysis
6.1 Global Tofacitinib Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Tofacitinib Sales by Region (2020-2031)
6.2.1 Global Tofacitinib Sales by Region: 2020-2025
6.2.2 Global Tofacitinib Sales by Region (2026-2031)
6.3 Global Tofacitinib Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Tofacitinib Sales Value by Region (2020-2031)
6.4.1 Global Tofacitinib Sales Value by Region: 2020-2025
6.4.2 Global Tofacitinib Sales Value by Region (2026-2031)
6.5 Global Tofacitinib Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Tofacitinib Sales Value (2020-2031)
6.6.2 North America Tofacitinib Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Tofacitinib Sales Value (2020-2031)
6.7.2 Europe Tofacitinib Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Tofacitinib Sales Value (2020-2031)
6.8.2 Asia-Pacific Tofacitinib Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Tofacitinib Sales Value (2020-2031)
6.9.2 South America Tofacitinib Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Tofacitinib Sales Value (2020-2031)
6.10.2 Middle East & Africa Tofacitinib Sales Value Share by Country, 2024 VS 2031
7 Tofacitinib Country-level Sales and Value Analysis
7.1 Global Tofacitinib Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Tofacitinib Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Tofacitinib Sales by Country (2020-2031)
7.3.1 Global Tofacitinib Sales by Country (2020-2025)
7.3.2 Global Tofacitinib Sales by Country (2026-2031)
7.4 Global Tofacitinib Sales Value by Country (2020-2031)
7.4.1 Global Tofacitinib Sales Value by Country (2020-2025)
7.4.2 Global Tofacitinib Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Tofacitinib Sales Value Growth Rate (2020-2031)
7.5.2 USA Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Tofacitinib Sales Value Growth Rate (2020-2031)
7.6.2 Canada Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Tofacitinib Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Tofacitinib Sales Value Growth Rate (2020-2031)
7.8.2 Germany Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Tofacitinib Sales Value Growth Rate (2020-2031)
7.9.2 France Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.9.3 France Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Tofacitinib Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Tofacitinib Sales Value Growth Rate (2020-2031)
7.11.2 Italy Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Tofacitinib Sales Value Growth Rate (2020-2031)
7.12.2 Spain Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Tofacitinib Sales Value Growth Rate (2020-2031)
7.13.2 Russia Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Tofacitinib Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Tofacitinib Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Tofacitinib Sales Value Growth Rate (2020-2031)
7.16.2 China Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.16.3 China Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Tofacitinib Sales Value Growth Rate (2020-2031)
7.17.2 Japan Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Tofacitinib Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Tofacitinib Sales Value Growth Rate (2020-2031)
7.19.2 India Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.19.3 India Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Tofacitinib Sales Value Growth Rate (2020-2031)
7.20.2 Australia Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Tofacitinib Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Tofacitinib Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Tofacitinib Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Tofacitinib Sales Value Growth Rate (2020-2031)
7.24.2 Chile Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Tofacitinib Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Tofacitinib Sales Value Growth Rate (2020-2031)
7.26.2 Peru Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Tofacitinib Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Tofacitinib Sales Value Growth Rate (2020-2031)
7.28.2 Israel Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Tofacitinib Sales Value Growth Rate (2020-2031)
7.29.2 UAE Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Tofacitinib Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Tofacitinib Sales Value Growth Rate (2020-2031)
7.31.2 Iran Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Tofacitinib Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Tofacitinib Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Tofacitinib Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Tofacitinib Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Pfizer
8.1.1 Pfizer Comapny Information
8.1.2 Pfizer Business Overview
8.1.3 Pfizer Tofacitinib Sales, Value and Gross Margin (2020-2025)
8.1.4 Pfizer Tofacitinib Product Portfolio
8.1.5 Pfizer Recent Developments
8.2 Globe Pharmaceuticals
8.2.1 Globe Pharmaceuticals Comapny Information
8.2.2 Globe Pharmaceuticals Business Overview
8.2.3 Globe Pharmaceuticals Tofacitinib Sales, Value and Gross Margin (2020-2025)
8.2.4 Globe Pharmaceuticals Tofacitinib Product Portfolio
8.2.5 Globe Pharmaceuticals Recent Developments
8.3 Drug International
8.3.1 Drug International Comapny Information
8.3.2 Drug International Business Overview
8.3.3 Drug International Tofacitinib Sales, Value and Gross Margin (2020-2025)
8.3.4 Drug International Tofacitinib Product Portfolio
8.3.5 Drug International Recent Developments
8.4 Delta Pharma Limited
8.4.1 Delta Pharma Limited Comapny Information
8.4.2 Delta Pharma Limited Business Overview
8.4.3 Delta Pharma Limited Tofacitinib Sales, Value and Gross Margin (2020-2025)
8.4.4 Delta Pharma Limited Tofacitinib Product Portfolio
8.4.5 Delta Pharma Limited Recent Developments
8.5 Beacon Pharmaceuticals
8.5.1 Beacon Pharmaceuticals Comapny Information
8.5.2 Beacon Pharmaceuticals Business Overview
8.5.3 Beacon Pharmaceuticals Tofacitinib Sales, Value and Gross Margin (2020-2025)
8.5.4 Beacon Pharmaceuticals Tofacitinib Product Portfolio
8.5.5 Beacon Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Tofacitinib Value Chain Analysis
9.1.1 Tofacitinib Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Tofacitinib Sales Mode & Process
9.2 Tofacitinib Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Tofacitinib Distributors
9.2.3 Tofacitinib Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.